Teriparatide use during an economic crisis: baseline data from the Greek cohort of the Extended Forsteo Observational Study (ExFOS).

Εκτυπώστε το άρθρο Email This Post
Post2PDF
BMC Musculoskelet Disord. 2015 Jun 5;16:136. doi: 10.1186/s12891-015-0600-8.

Teriparatide use during an economic crisis: baseline data from the Greek cohort
of the Extended Forsteo Observational Study (ExFOS).

Aloumanis K(1), Kapetanos G(2), Bartzis N(3), Drossinos V(4); Hellenic ExFOS
study group.

Collaborators: Adam A, Alexandridis T, Athanasakopoulos P, Bintas S, Dimopoulos
N, Dionyssiotis Y, Georgountzos A, Giannadakis P, Gouvas G, Kapetanos G,
Kaplanoglou T, Karagiannis A, Kleisiounis A, Kokkoris P, Kosmidis C, Kossyvakis
K, Krallis N, Matsouka A, Matzaroglou C, Meleteas E, Milonas C, Papaioannou N,
Papazisis Z, Repousis AP, Savvidis M, Temekonidis T, Trovas G, Tsakiri V, Tzoitou
M, Tzoutzopoulos A, Vandoros G, Ziabaras K.

Author information: 
(1)Department of Medical Research, Pharmaserve Lilly SACI, Arkadias 1 and
Megaloupoleos str, 14564 Kifissia, Athens, Greece. Aloumanis_kyriakos@lilly.com. 
(2)3rd Orthopedics University Clinic, Papageorgiou General Hospital,
Thessaloniki, Greece. geo.kapetanos@gmail.com. (3)Department of Medical Research,
Pharmaserve Lilly SACI, Arkadias 1 and Megaloupoleos str, 14564 Kifissia, Athens,
Greece. bartzis_nikolaos@lilly.com. (4)Department of Medical Research,
Pharmaserve Lilly SACI, Arkadias 1 and Megaloupoleos str, 14564 Kifissia, Athens,
Greece. drossinos_vangelis@lilly.com.

BACKGROUND: The Extended Forsteo Observational Study (ExFOS) is a multinational, 
non-interventional, prospective, observational study that aims to provide
real-life data on patients with osteoporosis treated with teriparatide for up to 
24 months. It includes the new indications of osteoporosis in men and
glucocorticoid-induced osteoporosis (GIOP). We describe the Greek subpopulation
enrolled in this study and compare it with a similar cohort from the previous
European Forsteo Observational Study (EFOS).
METHODS: Baseline data were collected from the Greek cohort of ExFOS. Data
included demographic characteristics, medical and osteoporosis history, disease
status, prior use of medications, back pain and quality of life.
RESULTS: Baseline data for 439 patients, enrolled at 31 sites, indicated the
majority of patients were females (92.3%), elderly [mean (standard deviation; SD)
age 70.1 (9.8) years] and slightly overweight [mean (SD) body mass index 26.7
(4.3) kg/m(2)], with very low bone mineral density (mean T-score <-3 in lumbar
spine or total hip) and at least one previous fracture (55.1% of patients). Of
the 439 patients, 19.8% were osteoporosis treatment naïve, 88.4% had experienced 
back pain during the previous 12 months, 68.1% had experienced back pain at least
fairly often during the previous month and 50.9% reported moderate to severe
limitation of activities due to back pain, with a mean (SD) of 4.2 (7.7) days
spent in bed because of back pain during the previous month. Most baseline
characteristics were numerically similar between the female ExFOS and EFOS
cohorts; however, the rate of enrolment was faster in ExFOS (by approximately
45%) and a history of fracture was recorded in 53.8% of female patients in ExFOS 
versus 74.5% in EFOS.
CONCLUSIONS: Greek patients prescribed teriparatide in ExFOS had severe
osteoporosis with a high risk of fractures and back pain. Female patients shared 
similarities with EFOS counterparts, reflecting a constant prescribing profile
for use of teriparatide, although a noticeable difference in fracture history
between the two study cohorts may indicate a change towards prescribing in less
severely affected patients. The economic crisis in Greece did not appear to
affect patient enrolment. Data are interpreted in the context of an observational
setting.

PMCID: PMC4457272


read the full text here:
ExFOS
Share
Εκτυπώστε το άρθρο Email This Post Post2PDF

web design

WebOlution